Recombinant Human Rho GDP Dissociation Inhibitor (GDI) Alpha

• Cat.No.: ARHGDIA-4913H
• Product Overview: Recombinant human ARHGDIA having a molecular mass of 54 kDa was expressed by E. coli.

Specification

• Cat. No.: ARHGDIA-4913H
• Description: ARHGDIA belongs to the family of rho-GDI or GDP-dissociation inhibitors for the Rho/Rac family of small G proteins; consisting of rhoGDI-1, D4-GDI/rhoGDI-2 and rhoGDI-3. It inhibits the release of GDP from the Rho proteins, essential for GTP-loading and activation of GTPase activity. ARHGDIA is located in the cytoplasm and is involved in the regulation of the membrane association and dissociation cycle of Rho/Rac proteins. It is known to be a substrate for caspase 3 during Fas-mediated apoptosis.
• Molecular Weight: 54 kDa
• Source: E. coli
• Species: Human
• Form: 100μg/ml in 50mM Tris-Acetate, pH 7.5, 1mM EDTA, 20% Glycerol.
• Appearance: Liquid
• Endotoxin Level: <0.1 ng/μg
• Purity: >90% as determined by SDS-PAGE and HPLC.
• Storage: Stable at -20°C or -80°C. Stable for 6-12 months. Avoid freeze-thaw cycles.
• Pathways: Axonal growth inhibition (RHOA activation); Axonal growth stimulation; CDC42 signaling events; Neurotrophin signaling pathway; RAC1 signaling pathway; Regulation of CDC42 activity; Regulation of RAC1 activity; Regulation of RhoA activity; Rho GTPase cycle; Signaling by Rho GTPases; Signalling by NGF; Vasopressin-regulated water reabsorption; p75 NTR receptor-mediated signalling; p75(NTR)-mediated signaling; p75NTR regulates axonogenesis

Gene Information

• Gene Name: ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha [ Homo sapiens ]
• Official Symbol: ARHGDIA
• Synonyms: ARHGDIA; Rho GDP dissociation inhibitor (GDI) alpha; GDIA1; MGC117248; RHOGDI; RHOGDI-1; rho GDI 1; rho GDP-dissociation inhibitor 1; rho-GDI alpha
• Gene ID: 396
• mRNA Refseq: NM_004309
• Protein Refseq: NP_004300
• MIM: 601925
• UniProt ID: P52565
• Chromosome Location: 17q25.3
• Function: GTPase activator activity; Rho GDP-dissociation inhibitor activity

Reviews

12/20/2020

the ARHGDIA protein is an exceptional tool for investigating the intricate mechanisms and pathogenesis of amyloid-related diseases.

02/06/2020

Their profound knowledge and expertise will undoubtedly help me overcome any challenges that arise, and their prompt assistance ensures a seamless progression of my research.

07/08/2019

the exemplary technical support provided by the manufacturer adds immense value to my experience.

03/15/2018

If needed, the availability of bulk purchase options further optimizes resource allocation, enabling me to conduct extensive experiments without compromising on quality.

01/14/2018

I am confident that their expertise and prompt assistance can help resolve any challenges I may encounter along the way.

11/18/2017

the ARHGDIA protein's exceptional quality, coupled with the manufacturer's outstanding technical support, ensures that it fulfills my experimental needs with utmost precision and efficacy.

07/09/2017

Their collaboration during trial design and data analysis enhances the reliability and significance of my research findings.

05/25/2016

Whether it's troubleshooting experimental hurdles or optimizing protocols, their dedicated team is there to guide me, ensuring smooth progress and successful outcomes.

Q&As

What research is being conducted on ARHGDIA?

Current research on ARHGDIA focuses on elucidating its role in various cellular processes and disease mechanisms. Scientists are investigating its involvement in cancer progression, metastasis, and therapeutic targeting potential. Additionally, studies are exploring the molecular mechanisms of ARHGDIA regulation and its interactions with other proteins and signaling pathways.

Are there any known diseases associated with dysregulation of ARHGDIA?

Yes, alterations in ARHGDIA expression or mutations in the ARHGDIA gene have been linked to certain diseases. In addition to neutrophil-specific granule deficiency (SGD), mentioned earlier, dysregulation of ARHGDIA has been observed in certain cancers, such as breast cancer and colorectal cancer. Abnormal ARHGDIA expression has also been associated with blood disorders and cardiovascular diseases.

Are there any potential therapeutic strategies targeting ARHGDIA?

Yes, targeting ARHGDIA has been explored as a potential therapeutic strategy in different diseases. For example, in cancer, inhibitors of Rho GTPases or RhoGEFs that interact with ARHGDIA have been investigated as potential anti-cancer agents. By inhibiting the activation of Rho GTPases, these compounds aim to disrupt signaling pathways involved in cancer progression and metastasis. Additionally, gene therapy approaches to modulate ARHGDIA expression levels have been explored as potential therapeutic interventions, particularly in diseases like neutrophil-specific granule deficiency.

Can changes in ARHGDIA expression levels be used as a diagnostic or prognostic marker?

There is emerging evidence suggesting that ARHGDIA expression levels may have diagnostic or prognostic value in certain diseases, particularly cancer. Alterations in ARHGDIA expression have been associated with tumor grade, metastatic potential, and patient survival outcomes in some studies. However, further research and validation are required before it can be considered a reliable clinical marker.

Is ARHGDIA involved in neural development or neurological disorders?

There is limited evidence suggesting the involvement of ARHGDIA in neural development and neurological disorders. Recent studies have found that ARHGDIA is expressed in the nervous system and may play a role in neuronal migration and axon guidance. However, further research is needed to fully understand its specific contributions to neural development and its potential involvement in neurological disorders.

Are there any animal models available to study ARHGDIA?

Yes, several animal models have been developed to study the function and roles of ARHGDIA. Knockout mouse models lacking ARHGDIA expression have been generated, allowing researchers to investigate the impact of ARHGDIA deficiency in various tissues and organs. These models have provided valuable insights into the physiological and pathological roles of ARHGDIA in different systems.

Are there any known interactions of ARHGDIA with other proteins or molecules?

Yes, ARHGDIA interacts with several proteins and molecules. It binds to Rho GTPases, specifically to their active GTP-bound form, preventing their activation. ARHGDIA also interacts with other regulatory proteins, such as Rho guanine nucleotide exchange factors (RhoGEFs) and Rho GTPase activating proteins (RhoGAPs), to modulate Rho GTPase activity. Additionally, ARHGDIA has been reported to interact with cytoskeletal proteins and participate in the regulation of actin dynamics.

Are there any known mutations or genetic variations in the ARHGDIA gene?

Yes, various mutations and genetic variations in the ARHGDIA gene have been identified. Some mutations can result in altered protein function, leading to diseases or developmental disorders. For example, a specific mutation in the ARHGDIA gene has been associated with a rare genetic disorder called neutrophil-specific granule deficiency (SGD), characterized by impaired neutrophil function.

Can ARHGDIA be targeted for therapeutic purposes?

The dysregulation of ARHGDIA in diseases, particularly cancer, suggests it could be a potential therapeutic target. Strategies to modulate ARHGDIA expression or activity may help regulate Rho GTPase signaling, leading to potential therapeutic benefits in cancer treatment. However, more research is needed to fully understand the therapeutic potential and feasibility of targeting ARHGDIA.